Ratings by Wedbush (Martin Fan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2026 | Eupraxia Pharmaceuticals | EPRX | New Coverage | Outperform (N/A) |
8.14 (6.87) |
-15.6% | Details | |
| 8/17/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
16.06 (7.41) |
-53.86% | Details | |
| 4/27/2026 | Oruka Therapeutics | ORKA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Outperform (N/A) |
19.00 (44.05) |
131.84% | Details | |
| 4/20/2026 | Nektar Therapeutics | NKTR | Maintain | Neutral (N/A) |
|
Details | ||
| 4/14/2026 | Sana Biotechnology | SANA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2026 | Nektar Therapeutics | NKTR | New Coverage | Neutral (N/A) |
74.34 (37.22) |
-49.93% | Details | |
| 2/9/2026 | Zura Bio Ltd. | ZURA | New Coverage | Outperform (N/A) |
6.01 (3.36) |
-44.09% | Details | |
| 11/25/2025 | ImageneBio | IMA | New Coverage | Underperform (N/A) |
6.91 (4.22) |
-38.93% | Details | |
| 11/25/2025 | Vor Biopharma, Inc. | VOR | New Coverage | Neutral (N/A) |
8.36 (18.26) |
118.42% | Details | |
| 10/27/2025 | Fate Therapeutics | FATE | Upgrade | Outperform (Neutral) |
1.65 (2.11) |
27.88% | Details | |
| 9/24/2025 | Sana Biotechnology | SANA | New Coverage | Outperform (N/A) |
3.26 (2.33) |
-28.53% | Details | |
| 7/9/2025 | Cartesian Therapeutics | RNAC | New Coverage | Outperform (N/A) |
11.30 (6.18) |
-45.31% | Details | |
| 5/28/2025 | Aclaris Therapeutis | ACRS | New Coverage | Outperform (N/A) |
1.27 (3.75) |
195.28% | Details | |
| 3/20/2025 | Zenas Biopharma | ZBIO | New Coverage | Outperform (N/A) |
8.25 (26.87) |
225.7% | Details |
